Data from EMC - Curated by Toby Galbraith - Last updated 11 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Neuropathic pain
Pregabalin Accord is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy
Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised anxiety disorder
Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

Visit Allergic Rhinitis


Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)


Related Content

More information

Category Value
Agency product number EMEA/H/C/004024
Orphan designation No
Date First Approved 28-08-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Accord Healthcare Limited